Want to see JP:4263 full AI Analyst Report?
4263 Stock Chart & Stats
¥821.00
¥24.00(3.84%)
At close: 4:00 PM EST
¥821.00
¥24.00(3.84%)
Day’s Range― - ―
52-Week Range¥587.00 - ¥1,231.00
Previous CloseN/A
Volume269.90K
Average Volume (3M)121.17K
Market Cap
¥14.62B
Enterprise Value¥8.74B
Total Cash (Recent Filing)¥4.40B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.79
Shares Outstanding16,868,100
10 Day Avg. Volume117,240
30 Day Avg. Volume121,170
Financial Highlights & Ratios
PEG Ratio2.02
Price to Book (P/B)2.35
Price to Sales (P/S)22.16
P/FCF Ratio-23.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)46.6
Revenue Forecast (FY)¥2.20B
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt and roughly 4.37B equity materially reduce financing risk and provide durable optionality to fund operations, R&D, or partnerships. This financial flexibility extends runway while management works to convert strong unit economics into sustainable profits.
Exceptional Gross MarginsApproximately 97% gross margins indicate strong unit economics typical of software-like digital health solutions. High gross profitability creates structural leverage: as revenue scales, fixed SG&A and R&D can be absorbed faster, enabling a clearer path to sustainable operating margins.
Lean Operating BaseA small headcount (43 employees) implies a lean cost structure and capital-efficient operations. This supports scalable growth with relatively low incremental overhead, improving the odds that revenue gains translate into margin recovery without proportional increases in fixed costs.
Bears Say
Deep, Persistent UnprofitabilityA roughly -64% net margin in 2025 reflects entrenched losses that erode equity and limit reinvestment; persistent unprofitability constrains strategic flexibility and requires sustained operational improvement to avoid dilution or asset-based financing over the medium term.
Worsening Cash BurnOperating and free cash flow turning deeply negative (-432M/-437M) and worsening versus prior years is a structural liquidity concern. Continued cash burn shortens runway, increases reliance on external funding, and raises execution risk unless margins improve or financing is secured.
Erosion Of Equity / Negative ROEDeclining equity and negative ROE (~-6.8% in 2025) signal capital erosion from ongoing losses. Reduced equity cushions limit strategic optionality and increase vulnerability to adverse shocks, making external financing more likely and potentially dilutive if losses persist.
4263 FAQ
What was SUSMED,Inc.’s price range in the past 12 months?
SUSMED,Inc. lowest stock price was ¥587.00 and its highest was ¥1231.00 in the past 12 months.
What is SUSMED,Inc.’s market cap?
SUSMED,Inc.’s market cap is ¥14.62B.
When is SUSMED,Inc.’s upcoming earnings report date?
SUSMED,Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 37 days.
How were SUSMED,Inc.’s earnings last quarter?
SUSMED,Inc. released its earnings results on May 08, 2026. The company reported -¥3.54 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.54.
Is SUSMED,Inc. overvalued?
According to Wall Street analysts SUSMED,Inc.’s price is currently Overvalued.
Does SUSMED,Inc. pay dividends?
SUSMED,Inc. does not currently pay dividends.
What is SUSMED,Inc.’s EPS estimate?
SUSMED,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SUSMED,Inc. have?
SUSMED,Inc. has 16,868,100 shares outstanding.
What happened to SUSMED,Inc.’s price movement after its last earnings report?
SUSMED,Inc. reported an EPS of -¥3.54 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.611%.
Which hedge fund is a major shareholder of SUSMED,Inc.?
Currently, no hedge funds are holding shares in JP:4263
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SUSMED,Inc.
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.